Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.57 -3.40%

-$0.24 today

Market cap
$104.19M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 1.39M

Average 0.65M

UNCY Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Unicycive Therapeutics, Inc.NASDAQ: UNCY

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 234.5% from a year ago

Total equity stood at $37.7M at the end of Q1 FY2026, up 234.5% from a year earlier and up 24.9% from the prior quarter.

Context

  • Total equity amounted to 58.5% of total assets at the end of Q1 FY2026, up 18.2 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +234.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$37.7M+24.9% QoQ
Last fiscal yearDec 2025
$30.2M+306.4% YoY
Year agoMar 2025
$11.27M+234.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+234.5%——
1 year+306.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
30.2M USD
Year-over-year change
+306.4%
4-year CAGR
+16.3%

Total Equity vs competitors

How UNCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +234.5% is the 3rd highest of 10, against a peer median of -40.1%.
  • Total equity amounts to 58.5% of total assets for UNCY, versus a peer median of 64.6%.
UNCY Competitors
Total Equity for UNCY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RLMDRelmada Therapeutics, Inc.Mar 2026$218.73M USD+874.7%-14.9%92.9%
IMUXImmunic, Inc.Mar 2026$151.23M USD+2960.5%—79.7%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$95.52M USD-40.4%-12.9%88.6%
VXRTVaxart, Inc.Mar 2026$94.12M USD+106.3%-7.4%52.3%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$87.97M USD-45.1%-24.8%91.1%
UNCYUnicycive Therapeutics, Inc.Mar 2026$37.7M USD+234.5%—58.5%
CBUSCibus, Inc.Mar 2026$35.48M USD-52.0%+44.5%10.9%
CAMPCAMP4 Therapeutics CorporationMar 2026$30.9M USD-40.1%—29.3%
BMEABiomea Fusion, Inc.Mar 2026$18.72M USD-34.9%-35.2%40.4%
HYFTMindWalk Holdings Corp.Jan 2026CA$14.98M CAD-40.4%-32.0%64.6%
Peer median (excluding UNCY) —-40.1%-14.9%64.6%

Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents16.58M455K9.7M26.14M29.2M
Short-term Investments000012.07M
Net Receivables00000
Inventory00000
Other Current Assets126K159K325K939K1.17M
Total Current Assets18.41M2.64M13.4M30.95M48.96M
Property, Plant & Equipment (Net)333K174K792K720K174K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets333K174K792K720K174K
Total Assets18.74M2.82M14.19M31.67M49.14M
Account Payables742K846K821K966K301K
Short-term Debt29K46K18K92K82K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities(29K)013.13M18.94M16.92M
Total Current Liabilities2.11M3.28M17.53M24.12M18.94M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities155K0466K117K0
Total Liabilities2.26M3.28M18M24.24M18.94M
Common Stock15K15K35K114K22K
Retained Earnings(15.94M)(34M)(64.54M)(101.27M)(127.83M)
Accumulated OCI0000(1K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity16.48M(466K)(3.81M)7.43M30.2M
Total Debt335K201K811K773K199K
Net Debt(16.24M)(254K)(8.89M)(25.37M)(29M)

Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Intrinsic Alpha fair value

Locked

Current Price

$3.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.